β-blocker ingestion

An evidence-based consensus guideline for out-of-hospital management

Paul M. Wax, Andrew R. Erdman, Peter Chyka, Daniel C. Keyes, E. Martin Caravati, Lisa Booze, Gwenn Christianson, Alan Woolf, Kent R. Olson, Anthony S. Manoguerra, Elizabeth J. Scharman, William G. Troutman

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

In 2003, US poison centers were contacted regarding ingestion of β-blockers by 15,350 patients including 3766 (25%) under 6 years of age; 7415 (48%) were evaluated in healthcare facilities and 33 died. An evidence-based expert consensus process was used to create this guideline. Relevant articles were abstracted by a trained physician researcher. The first draft of the guideline was created by the primary author. The entire panel discussed and refined the guideline before its distribution to secondary reviewers for comment. The panel then made changes in response to comments received. The objective of this guideline is to assist US poison center personnel in the appropriate out-of-hospital triage and management of patients with suspected ingestions of β-blockers by describing the process by which a β-blocker ingestion might be managed, identifying the key decision elements in managing cases of β-blocker ingestion, providing clear and practical recommendations that reflect the current state of knowledge, and identifying needs for research. This guideline applies to ingestion of β-blockers alone and is based on an assessment of current scientific and clinical information. The panel recognizes that specific patient care decisions may be at variance with this guideline and are the prerogative of the patient and health professionals providing care, considering all of the circumstances involved. Recommendations are in chronological order of likely clinical use; the grade of recommendation is in parentheses. 1) Patients with stated or suspected self-harm or who are the victims of a potentially malicious administration of β-blocker should be referred to an emergency department immediately. In general, this should occur regardless of the dose reported (Grade D). 2) Patients without evidence of self-harm should have further evaluation, including determination of the precise dose ingested, history of other medical conditions, and the presence of coingestants. Ingestion of either an amount that exceeds the usual maximum single therapeutic dose or an amount equal to or greater than the lowest reported toxic dose (whichever is lower) warrants consideration of referral to an emergency department. Ingestion of any excess dose of any β-blocker in combination with a calcium channel blocker or the ingestion of any excess dose by an individual with serious underlying cardiovascular disease also warrants referral to an emergency department (Grade C). 3) Do not induce emesis. Consider the oral administration of activated charcoal if it is available and no contraindications are present but do not delay transportation to administer charcoal (Grade A). 4) Asymptomatic patients who ingest more than the referral dose should be sent to an emergency department if the ingestion occurred within 6 hours of contacting the poison center for an immediate-release product other than sotalol, within 8 hours of contacting the poison center for a sustained-release product, and 12 hours if they took sotalol (Grade C). 5) Ambulance transportation is recommended for patients who are referred to emergency departments because of the potential for life-threatening complications of β-blocker overdose. Provide usual supportive care en route to the hospital, including intravenous fluids for hypotension (Grade D). 6) Follow-up calls should be made to determine outcome at appropriate intervals for up to 12-24 hours based on the judgment of the poison center staff (Grade D). 7) Asymptomatic patients who are referred to healthcare facilities should be monitored for at least 6 hours after ingestion if they took an immediate-release preparation other than sotalol, 8 hours if they took a sustained-release preparation, and 12 hours if they took sotalol Routine 24-hour admission of an asymptomatic patient who has unintentionally ingested a sustained-release preparation is not warranted (Grade D).

Original languageEnglish (US)
Pages (from-to)131-146
Number of pages16
JournalJournal of Toxicology - Clinical Toxicology
Volume43
Issue number3
DOIs
StatePublished - May 27 2005
Externally publishedYes

Fingerprint

Poisons
Sotalol
Eating
Guidelines
Delayed-Action Preparations
Hospital Emergency Service
Charcoal
Referral and Consultation
Ambulances
Calcium Channel Blockers
Delivery of Health Care
Health
Personnel
Triage
Patient Admission
Fluids
Hypotension
Vomiting
Oral Administration
Patient Care

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

β-blocker ingestion : An evidence-based consensus guideline for out-of-hospital management. / Wax, Paul M.; Erdman, Andrew R.; Chyka, Peter; Keyes, Daniel C.; Caravati, E. Martin; Booze, Lisa; Christianson, Gwenn; Woolf, Alan; Olson, Kent R.; Manoguerra, Anthony S.; Scharman, Elizabeth J.; Troutman, William G.

In: Journal of Toxicology - Clinical Toxicology, Vol. 43, No. 3, 27.05.2005, p. 131-146.

Research output: Contribution to journalReview article

Wax, PM, Erdman, AR, Chyka, P, Keyes, DC, Caravati, EM, Booze, L, Christianson, G, Woolf, A, Olson, KR, Manoguerra, AS, Scharman, EJ & Troutman, WG 2005, 'β-blocker ingestion: An evidence-based consensus guideline for out-of-hospital management', Journal of Toxicology - Clinical Toxicology, vol. 43, no. 3, pp. 131-146. https://doi.org/10.1081/CLT-200062475
Wax, Paul M. ; Erdman, Andrew R. ; Chyka, Peter ; Keyes, Daniel C. ; Caravati, E. Martin ; Booze, Lisa ; Christianson, Gwenn ; Woolf, Alan ; Olson, Kent R. ; Manoguerra, Anthony S. ; Scharman, Elizabeth J. ; Troutman, William G. / β-blocker ingestion : An evidence-based consensus guideline for out-of-hospital management. In: Journal of Toxicology - Clinical Toxicology. 2005 ; Vol. 43, No. 3. pp. 131-146.
@article{c518ea52afd94d8e87e6c0a8c5a3d35d,
title = "β-blocker ingestion: An evidence-based consensus guideline for out-of-hospital management",
abstract = "In 2003, US poison centers were contacted regarding ingestion of β-blockers by 15,350 patients including 3766 (25{\%}) under 6 years of age; 7415 (48{\%}) were evaluated in healthcare facilities and 33 died. An evidence-based expert consensus process was used to create this guideline. Relevant articles were abstracted by a trained physician researcher. The first draft of the guideline was created by the primary author. The entire panel discussed and refined the guideline before its distribution to secondary reviewers for comment. The panel then made changes in response to comments received. The objective of this guideline is to assist US poison center personnel in the appropriate out-of-hospital triage and management of patients with suspected ingestions of β-blockers by describing the process by which a β-blocker ingestion might be managed, identifying the key decision elements in managing cases of β-blocker ingestion, providing clear and practical recommendations that reflect the current state of knowledge, and identifying needs for research. This guideline applies to ingestion of β-blockers alone and is based on an assessment of current scientific and clinical information. The panel recognizes that specific patient care decisions may be at variance with this guideline and are the prerogative of the patient and health professionals providing care, considering all of the circumstances involved. Recommendations are in chronological order of likely clinical use; the grade of recommendation is in parentheses. 1) Patients with stated or suspected self-harm or who are the victims of a potentially malicious administration of β-blocker should be referred to an emergency department immediately. In general, this should occur regardless of the dose reported (Grade D). 2) Patients without evidence of self-harm should have further evaluation, including determination of the precise dose ingested, history of other medical conditions, and the presence of coingestants. Ingestion of either an amount that exceeds the usual maximum single therapeutic dose or an amount equal to or greater than the lowest reported toxic dose (whichever is lower) warrants consideration of referral to an emergency department. Ingestion of any excess dose of any β-blocker in combination with a calcium channel blocker or the ingestion of any excess dose by an individual with serious underlying cardiovascular disease also warrants referral to an emergency department (Grade C). 3) Do not induce emesis. Consider the oral administration of activated charcoal if it is available and no contraindications are present but do not delay transportation to administer charcoal (Grade A). 4) Asymptomatic patients who ingest more than the referral dose should be sent to an emergency department if the ingestion occurred within 6 hours of contacting the poison center for an immediate-release product other than sotalol, within 8 hours of contacting the poison center for a sustained-release product, and 12 hours if they took sotalol (Grade C). 5) Ambulance transportation is recommended for patients who are referred to emergency departments because of the potential for life-threatening complications of β-blocker overdose. Provide usual supportive care en route to the hospital, including intravenous fluids for hypotension (Grade D). 6) Follow-up calls should be made to determine outcome at appropriate intervals for up to 12-24 hours based on the judgment of the poison center staff (Grade D). 7) Asymptomatic patients who are referred to healthcare facilities should be monitored for at least 6 hours after ingestion if they took an immediate-release preparation other than sotalol, 8 hours if they took a sustained-release preparation, and 12 hours if they took sotalol Routine 24-hour admission of an asymptomatic patient who has unintentionally ingested a sustained-release preparation is not warranted (Grade D).",
author = "Wax, {Paul M.} and Erdman, {Andrew R.} and Peter Chyka and Keyes, {Daniel C.} and Caravati, {E. Martin} and Lisa Booze and Gwenn Christianson and Alan Woolf and Olson, {Kent R.} and Manoguerra, {Anthony S.} and Scharman, {Elizabeth J.} and Troutman, {William G.}",
year = "2005",
month = "5",
day = "27",
doi = "10.1081/CLT-200062475",
language = "English (US)",
volume = "43",
pages = "131--146",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - β-blocker ingestion

T2 - An evidence-based consensus guideline for out-of-hospital management

AU - Wax, Paul M.

AU - Erdman, Andrew R.

AU - Chyka, Peter

AU - Keyes, Daniel C.

AU - Caravati, E. Martin

AU - Booze, Lisa

AU - Christianson, Gwenn

AU - Woolf, Alan

AU - Olson, Kent R.

AU - Manoguerra, Anthony S.

AU - Scharman, Elizabeth J.

AU - Troutman, William G.

PY - 2005/5/27

Y1 - 2005/5/27

N2 - In 2003, US poison centers were contacted regarding ingestion of β-blockers by 15,350 patients including 3766 (25%) under 6 years of age; 7415 (48%) were evaluated in healthcare facilities and 33 died. An evidence-based expert consensus process was used to create this guideline. Relevant articles were abstracted by a trained physician researcher. The first draft of the guideline was created by the primary author. The entire panel discussed and refined the guideline before its distribution to secondary reviewers for comment. The panel then made changes in response to comments received. The objective of this guideline is to assist US poison center personnel in the appropriate out-of-hospital triage and management of patients with suspected ingestions of β-blockers by describing the process by which a β-blocker ingestion might be managed, identifying the key decision elements in managing cases of β-blocker ingestion, providing clear and practical recommendations that reflect the current state of knowledge, and identifying needs for research. This guideline applies to ingestion of β-blockers alone and is based on an assessment of current scientific and clinical information. The panel recognizes that specific patient care decisions may be at variance with this guideline and are the prerogative of the patient and health professionals providing care, considering all of the circumstances involved. Recommendations are in chronological order of likely clinical use; the grade of recommendation is in parentheses. 1) Patients with stated or suspected self-harm or who are the victims of a potentially malicious administration of β-blocker should be referred to an emergency department immediately. In general, this should occur regardless of the dose reported (Grade D). 2) Patients without evidence of self-harm should have further evaluation, including determination of the precise dose ingested, history of other medical conditions, and the presence of coingestants. Ingestion of either an amount that exceeds the usual maximum single therapeutic dose or an amount equal to or greater than the lowest reported toxic dose (whichever is lower) warrants consideration of referral to an emergency department. Ingestion of any excess dose of any β-blocker in combination with a calcium channel blocker or the ingestion of any excess dose by an individual with serious underlying cardiovascular disease also warrants referral to an emergency department (Grade C). 3) Do not induce emesis. Consider the oral administration of activated charcoal if it is available and no contraindications are present but do not delay transportation to administer charcoal (Grade A). 4) Asymptomatic patients who ingest more than the referral dose should be sent to an emergency department if the ingestion occurred within 6 hours of contacting the poison center for an immediate-release product other than sotalol, within 8 hours of contacting the poison center for a sustained-release product, and 12 hours if they took sotalol (Grade C). 5) Ambulance transportation is recommended for patients who are referred to emergency departments because of the potential for life-threatening complications of β-blocker overdose. Provide usual supportive care en route to the hospital, including intravenous fluids for hypotension (Grade D). 6) Follow-up calls should be made to determine outcome at appropriate intervals for up to 12-24 hours based on the judgment of the poison center staff (Grade D). 7) Asymptomatic patients who are referred to healthcare facilities should be monitored for at least 6 hours after ingestion if they took an immediate-release preparation other than sotalol, 8 hours if they took a sustained-release preparation, and 12 hours if they took sotalol Routine 24-hour admission of an asymptomatic patient who has unintentionally ingested a sustained-release preparation is not warranted (Grade D).

AB - In 2003, US poison centers were contacted regarding ingestion of β-blockers by 15,350 patients including 3766 (25%) under 6 years of age; 7415 (48%) were evaluated in healthcare facilities and 33 died. An evidence-based expert consensus process was used to create this guideline. Relevant articles were abstracted by a trained physician researcher. The first draft of the guideline was created by the primary author. The entire panel discussed and refined the guideline before its distribution to secondary reviewers for comment. The panel then made changes in response to comments received. The objective of this guideline is to assist US poison center personnel in the appropriate out-of-hospital triage and management of patients with suspected ingestions of β-blockers by describing the process by which a β-blocker ingestion might be managed, identifying the key decision elements in managing cases of β-blocker ingestion, providing clear and practical recommendations that reflect the current state of knowledge, and identifying needs for research. This guideline applies to ingestion of β-blockers alone and is based on an assessment of current scientific and clinical information. The panel recognizes that specific patient care decisions may be at variance with this guideline and are the prerogative of the patient and health professionals providing care, considering all of the circumstances involved. Recommendations are in chronological order of likely clinical use; the grade of recommendation is in parentheses. 1) Patients with stated or suspected self-harm or who are the victims of a potentially malicious administration of β-blocker should be referred to an emergency department immediately. In general, this should occur regardless of the dose reported (Grade D). 2) Patients without evidence of self-harm should have further evaluation, including determination of the precise dose ingested, history of other medical conditions, and the presence of coingestants. Ingestion of either an amount that exceeds the usual maximum single therapeutic dose or an amount equal to or greater than the lowest reported toxic dose (whichever is lower) warrants consideration of referral to an emergency department. Ingestion of any excess dose of any β-blocker in combination with a calcium channel blocker or the ingestion of any excess dose by an individual with serious underlying cardiovascular disease also warrants referral to an emergency department (Grade C). 3) Do not induce emesis. Consider the oral administration of activated charcoal if it is available and no contraindications are present but do not delay transportation to administer charcoal (Grade A). 4) Asymptomatic patients who ingest more than the referral dose should be sent to an emergency department if the ingestion occurred within 6 hours of contacting the poison center for an immediate-release product other than sotalol, within 8 hours of contacting the poison center for a sustained-release product, and 12 hours if they took sotalol (Grade C). 5) Ambulance transportation is recommended for patients who are referred to emergency departments because of the potential for life-threatening complications of β-blocker overdose. Provide usual supportive care en route to the hospital, including intravenous fluids for hypotension (Grade D). 6) Follow-up calls should be made to determine outcome at appropriate intervals for up to 12-24 hours based on the judgment of the poison center staff (Grade D). 7) Asymptomatic patients who are referred to healthcare facilities should be monitored for at least 6 hours after ingestion if they took an immediate-release preparation other than sotalol, 8 hours if they took a sustained-release preparation, and 12 hours if they took sotalol Routine 24-hour admission of an asymptomatic patient who has unintentionally ingested a sustained-release preparation is not warranted (Grade D).

UR - http://www.scopus.com/inward/record.url?scp=21044440250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044440250&partnerID=8YFLogxK

U2 - 10.1081/CLT-200062475

DO - 10.1081/CLT-200062475

M3 - Review article

VL - 43

SP - 131

EP - 146

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 3

ER -